Title:
Challenges and Recent Advances of Novel Chemical Inhibitors in Medulloblastoma Therapy

Simple item page
dc.contributor.authorAnand Maurya
dc.contributor.authorUpendra Kumar Patel
dc.contributor.authorJitendra Kumar Yadav
dc.contributor.authorVirender Pratap Singh
dc.contributor.authorAlka Agarwal
dc.date.accessioned2026-02-07T11:13:21Z
dc.date.issued2022
dc.description.abstractMedulloblastoma is a common term used for the juvenile malignant brain tumor, and its treatment is exciting due to different genetic origins, improper transportation of drug across the blood-brain barrier, and chemo-resistance with various side effects. Currently, medulloblastoma divided into four significant subsections (Wnt, Shh, Group 3, and Group 4) is based on their hereditary modulation and histopathological advancement. In this chapter, we tried to combine several novel chemical therapeutic agents active toward medulloblastoma therapy. All these compounds have potent activity to inhibit the medulloblastoma. © 2022, The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
dc.identifier.doi10.1007/978-1-0716-1952-0_13
dc.identifier.issn10643745
dc.identifier.urihttps://doi.org/10.1007/978-1-0716-1952-0_13
dc.identifier.urihttps://dl.bhu.ac.in/bhuir/handle/123456789/42785
dc.publisherHumana Press Inc.
dc.subjectBrain tumor
dc.subjectIC<sub>50</sub> value
dc.subjectMedulloblastoma
dc.subjectShh group
dc.subjectWnt group
dc.titleChallenges and Recent Advances of Novel Chemical Inhibitors in Medulloblastoma Therapy
dc.typePublication
dspace.entity.typeBook chapter

Files

Collections

2022
An Initiative by BHU – Central Library
Powered by Dspace